CELLECTIS

The CRISPR and Cas gene market was valued at $3.3 billion in 2023, with a CAGR of 20.38% since 2018. It's projected to reach $8.8 billion by 2028 and $24.6 billion by 2033. Growth drivers include personalized medicine, genetic disorders, and synthetic biology. Challenges include regulatory complexities and healthcare access in developing countries. The market is segmented by type, application, product type, end use, and service type, with various segments showing significant growth potential. North America leads the market, but Asia-Pacific and Africa are expected to grow fastest. The market is dominated by large players like Danaher Corporation and Agilent Technologies Inc.

The gene editing market is projected to grow from USD 4.66 billion in 2024 to USD 7.59 billion by 2029, driven by advancements in technologies and expanding applications. The products segment, including kits, reagents, libraries, and software, dominates the market. CRISPR technology leads, while Asia Pacific shows the highest growth rate due to increased R&D and government funding. Challenges include off-target effects and scalability issues.

The Gene Switch Market is projected to grow from USD 0.78 Bn in 2024 to USD 1.78 Bn by 2031, with a CAGR of 11.6%. CoherentMI's report provides a comprehensive analysis of market trends, competitive landscape, and key players like Novartis, Pfizer, and Gilead Sciences.

The Cas nuclease market is forecasted to grow from $2.75 billion in 2023 to $6.56 billion by 2028 at a CAGR of 19.0%, driven by advancements in genome editing, increased biotechnology funding, and demand for personalized medicine.

Beam Therapeutics acknowledges a patient death in a Phase 1/2 trial for sickle cell disease, attributing it to pre-conditioning, not the base-editing treatment. AstraZeneca, UT, and LIVESTRONG report successful therapeutic genome editing in mouse liver via lipid nanoparticles. Korean researchers find base and prime editors produce fewer large DNA deletions than Cas9 nucleases. YolTech demonstrates effective mRNA delivery to bone marrow cells for blood disorder treatment. Japanese scientists develop a curative strategy for congenital purpura fulminans using engineered APC. US-France team identifies key host factors enhancing rotavirus vaccine production. Allogene Therapeutics shares positive Phase 1 data for renal cell carcinoma treatment. Cellectis presents strategies to enhance CAR T-cell efficacy in solid tumors. Caszyme and Integra Therapeutics enter a licensing agreement for safer gene therapies. Industry updates include financial results and clinical trial progress from various companies. CRISPR genome engineering symposium to feature latest advancements. CRISPR gene editing can integrate mitochondrial DNA into the nuclear genome, but exonucleases can mitigate this. HuidaGene Therapeutics' CRISPR-Cas13 RNA-editing therapy for macular degeneration is accepted by the FDA.

Cellectis reported a $108 million increase in cash reserves to $264 million, driven by a $140 million investment from AstraZeneca. The collaboration initiated three new R&D programs, including two allogeneic CAR T therapies and an in vivo gene therapy. Cellectis is deprioritizing the UCART123 program to focus on more promising assets and extend its cash runway to 2027. The company plans to present Phase I data in 2025 and is committed to open communication with stakeholders.

Gene therapy clinical trials gain momentum with over 180 companies advancing treatments, leveraging technologies like CRISPR/Cas9 for precision. Key therapies include ZOLGENSMA for spinal muscular atrophy and LUXTURNA for inherited retinal diseases. Challenges include immune reactions, long-term effects, and high costs, necessitating ethical oversight and equitable access.

Dana-Fiona Armour wins Sigg Art Prize for AI-integrated art, Alvinella Ophis, exploring biotechnology and contemporary art. The Sigg Art Foundation views AI as transformative, akin to photography's impact during the industrial revolution.

Cellectis developed TALEN-edited allogeneic CAR-T cells with an IF/THEN logic-gated system to target solid tumours, addressing challenges like CAFs and off-target toxicity. The dual-control mechanism activates CAR-T cells only in specific tumour conditions, enhancing precision and safety.

The Global TIL Therapy Market is projected to grow from USD 0.092 Billion in 2024 to USD 9.20 Billion by 2031, driven by personalized immunotherapy advancements, increasing cancer research investments, and successful clinical trials. Key players include Iovance Biotherapeutics, Instil Bio, Obsidian Therapeutics, Cellectis, and Cellular Biomedicine Group.